Barr launches generic Fosamax following final FDA approval
MONTVALE, N.J. Barr Laboratories has launched a generic version of Merck’s osteoporosis drug Fosamax tablets, 70 mg after receiving final approval from the Food and Drug Administration.
Barr is entitled to share 180 days of marketing exclusivity for its 70 mg alendronate sodium product. Barr will share this exclusivity with Teva and any authorized generics that Merck plans on introducing with another company.
“Barr is pleased to be able to provide people suffering from osteoporosis and Paget’s disease with a more affordable generic alternative,” said Bruce Downey, Barr’s chairman and chief executive officer. “This is particularly critical as our elderly population increases and seeks to maintain their quality of life in their advanced years.”
Fosamax 70 mg had annual sales of approximately $1.7 billion in the U.S., based on IMS sales data for the 12 months that ended November 2007.
Parata launches PACMED C30 packaging technology
DURHAM, N.C. Parata Systems has launched its new product, the PACMED C30, which is a packaging technology used to extend the safety and convenience of its onePAC packaging system.
onePac is a strip that contains information like patients’ medications, patient names, pill descriptions and time of day to take a dose of the medication. On the strip, up to 19 lines of information can be held. The goal of the strips are to remind patients who take multiple medications when to take what medications and how much of each medication.
The PACMED C30 expands on the technology of the onePAC by combining multiple onePAC strips together for easy access by patients. PACMED C30 is efficient and accurate, generating up to 60 unit-dose or 50 multi-dose packages a minute.
“Adherence is a critical touch point in the circle of pharmacy care, and Parata’s launch of PACMED C30 offers an exciting new way for pharmacies to extend their care by improving patient adherence, safety and convenience,” says Tom Rhoads, executive vice president for customer and market strategies at Parata Systems.
Teva announces availablility of generic Fosamax
NORTH WALES, Pa. Teva has announced the introduction and availability of alendronate sodium tablets.
This is the generic version of the osteoporosis drug Fosamax by Merck. The drug will be available in 5 mg, 10 mg, 35 mg, 40 mg and 70 mg strengths.
“Our customers count on Teva for a continuous supply of new generic products,” stated John Denman, vice president of sales and marketing. “With the launch of alendronate sodium tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”